L-AP4: Difference between revisions
Appearance
Content deleted Content added
m Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script) |
Changed Category:Amino acids to Category:Alpha-Amino acids |
||
(10 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
| verifiedrevid = 451227757 |
| verifiedrevid = 451227757 |
||
| IUPAC_name = ( |
| IUPAC_name = (2''S'')-2-Amino-4-phosphonobutanoic acid |
||
| image = L- |
| image = L-2-amino-4-phosphonobutyric acid L-AP4.svg |
||
| width = 200 |
| width = 200 |
||
Line 27: | Line 28: | ||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|correct| |
| CAS_number_Ref = {{cascite|correct|CAS}} |
||
| CAS_number = 23052-81-5 |
| CAS_number = 23052-81-5 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = C8M58SS68H |
|||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
Line 35: | Line 38: | ||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID_Ref = {{chemspidercite| |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 156157 |
| ChemSpiderID = 156157 |
||
| synonyms = <small>L</small>-2-Amino-4-phosphonobutyric acid |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=4 | H=10 | N=1 | O=5 | P=1 |
| C=4 | H=10 | N=1 | O=5 | P=1 |
||
| molecular_weight = 183.099 g/mol |
|||
| smiles = C(CP(=O)(O)O)[C@@H](C(=O)O)N |
| smiles = C(CP(=O)(O)O)[C@@H](C(=O)O)N |
||
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
||
Line 48: | Line 51: | ||
}} |
}} |
||
'''L- |
'''L-AP4''' ('''<small>L</small>-2-amino-4-phosphonobutyric acid''') is a drug used in scientific research, which acts as a group-selective [[agonist]] for the group III [[metabotropic glutamate receptor]]s ([[Metabotropic glutamate receptor 4|mGluR<sub>4</sub>]]<sub>/</sub>[[Metabotropic glutamate receptor 6|<sub>6</sub>]]<sub>/</sub>[[Metabotropic glutamate receptor 7|<sub>7</sub>]]<sub>/</sub>[[Metabotropic glutamate receptor 8|<sub>8</sub>]]). It was the first ligand found to act as an agonist selective for this group of mGlu receptors,<ref>{{cite journal | vauthors = Thomsen C | title = The L-AP4 receptor | journal = General Pharmacology | volume = 29 | issue = 2 | pages = 151–8 | date = August 1997 | pmid = 9251893 | doi = 10.1016/S0306-3623(96)00417-X }}</ref> but does not show selectivity between the different mGluR Group III subtypes. It is widely used in the study of this receptor family and their various functions.<ref>{{cite journal | vauthors = Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M | title = Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease | journal = The Journal of Neuroscience | volume = 27 | issue = 25 | pages = 6701–11 | date = June 2007 | pmid = 17581957 | pmc = 6672706 | doi = 10.1523/JNEUROSCI.0299-07.2007 | url = https://hal.archives-ouvertes.fr/hal-00165896/document }}</ref><ref>{{cite journal | vauthors = Macinnes N, Duty S | title = Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo | journal = European Journal of Pharmacology | volume = 580 | issue = 1–2 | pages = 95–9 | date = February 2008 | pmid = 18035348 | doi = 10.1016/j.ejphar.2007.10.030 }}</ref><ref>{{cite journal | vauthors = Zhang HM, Chen SR, Pan HL | title = Effects of activation of group III metabotropic glutamate receptors on spinal synaptic transmission in a rat model of neuropathic pain | journal = Neuroscience | volume = 158 | issue = 2 | pages = 875–84 | date = January 2009 | pmid = 19017536 | pmc = 2649787 | doi = 10.1016/j.neuroscience.2008.10.042 }}</ref><ref>{{cite journal | vauthors = Maciejak P, Szyndler J, Turzyńska D, Sobolewska A, Taracha E, Skórzewska A, Lehner M, Bidziński A, Hamed A, Wisłowska-Stanek A, Płaźnik A | display-authors = 6 | title = The effects of group III mGluR ligands on pentylenetetrazol-induced kindling of seizures and hippocampal amino acids concentration | journal = Brain Research | volume = 1282 | pages = 20–7 | date = July 2009 | pmid = 19481536 | doi = 10.1016/j.brainres.2009.05.049 | s2cid = 20844494 }}</ref> |
||
==References== |
== References == |
||
{{Reflist|2}} |
{{Reflist|2}} |
||
{{Metabotropic glutamate receptor modulators}} |
|||
{{Glutamatergics}} |
|||
[[Category:Amino acids]] |
[[Category:Alpha-Amino acids]] |
||
[[Category:Phosphonic acids]] |
[[Category:Phosphonic acids]] |
||
[[Category:MGlu4 receptor agonists]] |
[[Category:MGlu4 receptor agonists]] |
||
Line 61: | Line 64: | ||
[[Category:MGlu7 receptor agonists]] |
[[Category:MGlu7 receptor agonists]] |
||
[[Category:MGlu8 receptor agonists]] |
[[Category:MGlu8 receptor agonists]] |
||
{{nervous-system-drug-stub}} |
{{nervous-system-drug-stub}} |
Latest revision as of 16:54, 17 September 2023
Clinical data | |
---|---|
Other names | L-2-Amino-4-phosphonobutyric acid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.164.384 |
Chemical and physical data | |
Formula | C4H10NO5P |
Molar mass | 183.100 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
L-AP4 (L-2-amino-4-phosphonobutyric acid) is a drug used in scientific research, which acts as a group-selective agonist for the group III metabotropic glutamate receptors (mGluR4/6/7/8). It was the first ligand found to act as an agonist selective for this group of mGlu receptors,[1] but does not show selectivity between the different mGluR Group III subtypes. It is widely used in the study of this receptor family and their various functions.[2][3][4][5]
References
[edit]- ^ Thomsen C (August 1997). "The L-AP4 receptor". General Pharmacology. 29 (2): 151–8. doi:10.1016/S0306-3623(96)00417-X. PMID 9251893.
- ^ Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M (June 2007). "Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease". The Journal of Neuroscience. 27 (25): 6701–11. doi:10.1523/JNEUROSCI.0299-07.2007. PMC 6672706. PMID 17581957.
- ^ Macinnes N, Duty S (February 2008). "Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo". European Journal of Pharmacology. 580 (1–2): 95–9. doi:10.1016/j.ejphar.2007.10.030. PMID 18035348.
- ^ Zhang HM, Chen SR, Pan HL (January 2009). "Effects of activation of group III metabotropic glutamate receptors on spinal synaptic transmission in a rat model of neuropathic pain". Neuroscience. 158 (2): 875–84. doi:10.1016/j.neuroscience.2008.10.042. PMC 2649787. PMID 19017536.
- ^ Maciejak P, Szyndler J, Turzyńska D, Sobolewska A, Taracha E, Skórzewska A, et al. (July 2009). "The effects of group III mGluR ligands on pentylenetetrazol-induced kindling of seizures and hippocampal amino acids concentration". Brain Research. 1282: 20–7. doi:10.1016/j.brainres.2009.05.049. PMID 19481536. S2CID 20844494.